As an important component of eIF4F, eIF4A1 plays a vital role in malignant transformation and progression, and recent evidence has shown that eIF4A1 is dysregulated in gastric cancer (GC) (Gao et al., 2020), colorectal cancer (Li W. et al., 2017), cervical cancer (Liang et al., 2014), hepatocellular carcinoma (Zhang et al., 2020), ovarian cancer (Zhang et al., 2018), and other cancers. Here, EIF4A1 is linked to ovarian carcinoma.